Impact of diverse immune evasion mechanisms of cancer cells on T cells engaged by EpCAM/CD3-bispecific antibody construct AMG 110

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Deisting, Wibke ^a   Raum, Tobias ^a   Kufer, Peter ^a   Baeuerle, Patrick A ^b   Münz, Markus ^a  

^a Amgen Research GmbH   (Germany)

^b MPM Capital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; PROTEIN BCL 2; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; BISPECIFIC ANTIBODY; CD274 PROTEIN, HUMAN; CD3 ANTIGEN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; SERPINB9 PROTEIN, HUMAN; TUMOR ANTIGEN;

ARTICLE; CANCER CELL; CD3+ T LYMPHOCYTE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE EVASION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; T LYMPHOCYTE; TARGET CELL; TUMOR ESCAPE; ANIMAL; CHO CELL LINE; CRICETULUS; CYTOTOXICITY; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD274; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; EPITHELIAL CELL ADHESION MOLECULE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNE EVASION; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SERPINS; T-LYMPHOCYTES; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84949818742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141669     Document Type: Article

References (39)

1. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(10):2346-57. Epub 2005/04/01. doi: 10.1200/jco.2005.00.240 PMID: 15800326; PubMed Central PMCID: PMCPmc1475951.
2. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine. 2013; 369(2):134-44. Epub 2013/06/04. doi: 10.1056/NEJMoa1305133 PMID: 23724846; PubMed Central PMCID: PMCPmc4126516.
3. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(34):5763-71. Epub 2009/11/04. doi: 10.1200/jco. 2009.24.3675 PMID: 19884534.
4. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences. 2013; 1291:1-13. Epub 2013/06/19. doi: 10.1111/nyas.12180 PMID: 23772560; PubMed Central PMCID: PMCPmc3910157.
5. Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Current opinion in molecular therapeutics. 2009; 11(1):22-30. Epub 2009/01/27. PMID: 19169956.
6. Kischel R, Hausmann S, Baeuerle P, Kufer P. Abstract #3252: Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110. AACR Meeting Abstracts. 2009; 2009(2-Annual-Meeting):3252-.
7. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Current opinion in chemical biology. 2013; 17(3):385-92. Epub 2013/04/30. doi: 10.1016/j.cbpa.2013.03.029 PMID: 23623807.
8. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the Tcell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(18):2493-8. Epub 2011/05/18. doi: 10.1200/jco.2010.32.7270 PMID: 21576633.
9. Schlegel P, Lang P, Zugmaier G, Ebinger M, Kreyenberg H, Witte KE, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014; 99(7):1212-9. Epub 2014/04/15. doi: 10.3324/haematol.2013.100073 PMID: 24727818; PubMed Central PMCID: PMCPmc4077083.
10. Fiedler WM, Ritter B, Seggewiss R, Bokemeyer C, Fettes P, Klinger M, et al. Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. ASCO Meeting Abstracts. 2010; 28(15-suppl):2573.
11. Fiedler WM, Wolf M, Kebenko M, Goebeler M-E, Ritter B, Quaas A, et al. A phase I study of EpCAM/ CD3-bispecific antibody (MT110) in patients with advanced solid tumors. ASCO Meeting Abstracts. 2012; 30(15-suppl):2504.
12. Muller L, Kiessling R, Rees RC, Pawelec G. Escape mechanisms in tumor immunity: an update. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer. 2002; 21(4):277-330. Epub 2003/01/04. PMID: 12510961.
13. Topfer K, Kempe S, Muller N, Schmitz M, Bachmann M, Cartellieri M, et al. Tumor evasion from T cell surveillance. Journal of biomedicine & biotechnology. 2011; 2011:918471. doi: 10.1155/2011/918471 PMID: 22190859; PubMed Central PMCID: PMC3228689.
14. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PDL1 antibody in patients with advanced cancer. The New England journal of medicine. 2012; 366 (26):2455-65. Epub 2012/06/05. doi: 10.1056/NEJMoa1200694 PMID: 22658128; PubMed Central PMCID: PMCPmc3563263.
15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366 (26):2443-54. Epub 2012/06/05. doi: 10.1056/NEJMoa1200690 PMID: 22658127; PubMed Central PMCID: PMCPmc3544539.
16. Zhang B. CD73: a novel target for cancer immunotherapy. Cancer research. 2010; 70(16):6407-11. Epub 2010/08/05. doi: 10.1158/0008-5472.can-10-1544 PMID: 20682793; PubMed Central PMCID: PMCPmc2922475.
17. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol. 2008; 32 (3):527-35. Epub 2008/02/23. PMID: 18292929.
18. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunological reviews. 2008; 226:205-18. doi: 10.1111/j.1600-065X.2008.00706.x PMID: 19161426; PubMed Central PMCID: PMC2724982.
19. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer cell. 2005; 8(5):369-80. Epub 2005/11/16. doi: 10.1016/j.ccr.2005.10. 012 PMID: 16286245.
20. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(20):11515-20. Epub 2001/09/20. doi: 10.1073/pnas.201398198 PMID: 11562487; PubMed Central PMCID: PMCPmc58761.
21. Goping IS, Barry M, Liston P, Sawchuk T, Constantinescu G, Michalak KM, et al. Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity. 2003; 18 (3):355-65. Epub 2003/03/22. PMID: 12648453.
22. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. The Journal of experimental medicine. 2002; 196(4):447-57. Epub 2002/08/21. PMID: 12186837; PubMed Central PMCID: PMCPmc2196057.
23. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. The Journal of clinical investigation. 2007; 117(5):1147-54. PubMed Central PMCID: PMC1857253.
24. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Molecular immunology. 2006; 43(8):1129-43. Epub 2005/09/06. doi: 10.1016/j.molimm.2005.07.034 PMID: 16139892.
25. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. Journal of the National Cancer Institute. 1973; 51(5):1417-23. Epub 1973/11/01. PMID: 4357758.
26. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, et al. Characterization of a new primary human pancreatic tumor line. Cancer investigation. 1986; 4(1):15-23. Epub 1986/01/01. PMID: 3754176.
27. Sekiguchi M, Sakakibara K, Fujii G. Establishment of cultured cell lines derived from a human gastric carcinoma. The Japanese journal of experimental medicine. 1978; 48(1):61-8. Epub 1978/02/01. PMID: 209229.
28. Fogh J. Human tumor cells in vitro. New York: Plenum Press. 1975.
29. Leibovitz A, Stinson JC, McCombs WB 3rd, McCoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer research. 1976; 36(12):4562-9. Epub 1976/12/11. PMID: 1000501.
30. Yasui H, Takai K, Yoshida R, Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 1986; 83(17):6622-6. Epub 1986/09/01. PMID: 2428037; PubMed Central PMCID: PMCPmc386556.
31. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer research. 2004; 64 (3):1140-5. Epub 2004/02/12. PMID: 14871849.
32. Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific singlechain antibody construct. Cancer immunology, immunotherapy: CII. 2007; 56(10):1551-63. Epub 2007/02/21. doi: 10.1007/s00262-007-0298-z PMID: 17310380.
33. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Molecular immunology. 2006; 43(6):763-71. Epub 2005/12/20. doi: 10.1016/j.molimm.2005.03.007 PMID: 16360021.
34. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. Journal of immunotherapy (Hagerstown, Md: 1997). 2007; 30(8):798-807. Epub 2007/12/01. doi: 10.1097/CJI. 0b013e318156750c PMID: 18049331.
35. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501(7467):338-45. Epub 2013/09/21. doi: 10.1038/ nature12625 PMID: 24048066.
36. Real LM, Jimenez P, Kirkin A, Serrano A, Garcia A, Canton J, et al. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer immunology, immunotherapy: CII. 2001; 49(11):621-8. Epub 2001/02/28. PMID: 11225993.
37. Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. Journal of immunotherapy (Hagerstown, Md: 1997). 2009; 32(5):452-64. Epub 2009/07/18. doi: 10.1097/CJI.0b013e3181a1c097 PMID: 19609237.
38. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cellengaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012; 119(26):6226-33. Epub 2012/05/18. doi: 10.1182/blood-2012-01-400515 PMID: 22592608.
39. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. European journal of immunology. 2002; 32 (3):634-43. Epub 2002/02/22.